Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Good afternoon. Thank you very much for being here with us today. My name is Raji Gunasekera. I'm an associate on the health care team at JPMorgan. And today, I'm pleased to introduce Vanda Pharmaceuticals, and we have their CFO, Kevin Moran. Thank you.
Thanks, Raji, and thanks to the entire JPMorgan team for having us today. Very excited to talk to you about the progress of our company, Vanda Pharmaceuticals, as well as our upcoming milestones.
Turning now to our forward-looking statements. Folks should be aware of these as we review the slides in the presentation today. Beginning with our commercialized products. Vanda has 2 products on the market, HETLIOZ and Fanapt. HETLIOZ capsules are approved in the U.S. for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in patients with Smith-Magenis Syndrome in adults. Additionally, the capsules are approved in Europe for Non-24-Hour Sleep-Wake Disorder. And in addition to HETLIOZ capsules, the HETLIOZ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |